ImageneBio (NASDAQ:IMA - Get Free Report) was upgraded by analysts at HC Wainwright to a "strong-buy" rating in a research report issued on Friday,Zacks.com reports.
Several other research firms also recently issued reports on IMA. Wedbush reaffirmed an "underperform" rating on shares of ImageneBio in a report on Monday, May 11th. Wall Street Zen cut ImageneBio from a "sell" rating to a "strong sell" rating in a research note on Sunday, May 17th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of ImageneBio in a research report on Monday, June 29th. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, ImageneBio has an average rating of "Hold" and a consensus price target of $29.00.
Get Our Latest Analysis on ImageneBio
ImageneBio Trading Down 1.8%
IMA opened at $5.51 on Friday. ImageneBio has a 1-year low of $3.94 and a 1-year high of $14.34. The stock has a market capitalization of $62.54 million, a PE ratio of -1.20 and a beta of 0.76. The firm has a 50-day moving average price of $5.79 and a two-hundred day moving average price of $5.86.
ImageneBio (NASDAQ:IMA - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.90) by $0.27. On average, research analysts predict that ImageneBio will post -3.07 EPS for the current year.
Institutional Investors Weigh In On ImageneBio
Several institutional investors have recently modified their holdings of the business. Blue Owl Capital Holdings LP bought a new stake in shares of ImageneBio during the second quarter worth approximately $5,414,000. Deep Track Capital LP bought a new position in ImageneBio in the third quarter valued at approximately $7,160,000. Cable Car Capital LP bought a new position in ImageneBio in the second quarter valued at approximately $4,611,000. Trails Edge Capital Partners LP acquired a new stake in ImageneBio during the 2nd quarter worth $1,663,824,000. Finally, Vanguard Group Inc. acquired a new stake in ImageneBio during the 3rd quarter worth $1,902,000. Institutional investors and hedge funds own 75.00% of the company's stock.
About ImageneBio
(
Get Free Report)
ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider ImageneBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImageneBio wasn't on the list.
While ImageneBio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
